Rotavirus vaccine

PreclinicalVaccine

Sanofi

Rotavirus vaccine is one of 20 biologic programs targeting Gastroenteritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroenteritisActive, not recruiting

GastroenteritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Gastroenteritis

#DrugCompanyPhaseTrials

Zofran

Novartis

Approved

8 2

Cipro

Bayer

Approved

—3

Reglan

IIstituto Clinico Humanitas

Approved

—4

Hyoscine-N-Butylbromide

Boehringer Ingelheim

Approved

2 5

Dimenhydrinate

SSt. Justine's Hospital

Approved

1 6

Rotarix ™

GSK

Phase 3

1 7

Domperidone

Johnson & Johnson

Phase 3

1 8

Prulifloxacin

Merck & Co.

Phase 3

1 9

Xolair

Roche

Phase 2

1 10

Papaverine

WWestern Galilee Hospital-Nahariya

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Active, not recruiting

Meningococcal Disease

NCT06647407

Q1 2028

Phase 3Recruiting

Vaccine

NCT07348692

Clinical

Trials by Indication[1]

Vaccine6 trials

A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy

Unknown status·FFederico II University··NCT05212935·2,000 enrolled

Baby Vaccine Study (Sched3)

Completed·UUniversity of Oxford·Phase 2·NCT02482636·189 enrolled

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07348692·896 enrolled

Show 3 more trials

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Completed· Sanofi logo

Sanofi·Phase 2·NCT01049035·580 enrolled

To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV

Completed· GSK logo

GSK·Phase 2·NCT00346892·450 enrolled

Introduction of an Oral Live Human Rotavirus (Rotarix) Vaccine in Matlab

Completed·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 4·NCT00737503·4,550 enrolled

Rotavirus Vaccine4 trials

Rotavirus Vaccine Produced by Butantan Institute

Completed·BButantan Institute·Phase 1·NCT00981669·80 enrolled

Immunogenicity of Rotavirus Vaccine

Completed·PPATH·Phase 4·NCT01199874·1,140 enrolled

Development of a Live Attenuated Rotavirus Vaccine as a Human Infection Challenge Model

Completed·CCentre for Infectious Disease Research in Zambia·N/A·NCT04123119·22 enrolled

Show 1 more trial

The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine

Unknown status·SSichuan Center for Disease Control and Prevention·Phase 4·NCT02153866·2,800 enrolled

Immunogenicity3 trials

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico

Completed· Sanofi logo

Sanofi·Phase 3·NCT03630705·525 enrolled

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01480258·1,315 enrolled

Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates

Completed·PPT Bio Farma·Phase 1·NCT03462108·100 enrolled

Gastroenteritis2 trials

Gastroenteritis From Rotavirus Infection in Brazilian Children Less Than 5 Years of Age (Study V260-031).

Terminated· Merck & Co. logo

Merck & Co.··NCT01195844·230 enrolled

Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger

Completed·EEpicentre·Phase 3·NCT02145000·6,586 enrolled

Pediatric2 trials

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Completed· Sanofi logo

Sanofi·Phase 3·NCT05794230·1,528 enrolled

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Completed· Sanofi logo

Sanofi·Phase 3·NCT03673462·2,797 enrolled

3 more indications

Vaccines2 trials

To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines

Completed· GSK logo

GSK·Phase 3·NCT00140686·3,994 enrolled

Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines

Completed·PPATH·Phase 4·NCT01616693·620 enrolled

Respiratory Syncytial Virus1 trial

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Terminated· Sanofi logo

Sanofi·Phase 3·NCT06397768·2,226 enrolled

Meningococcal Disease1 trial

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Active, not recruiting· Sanofi logo

Sanofi·Phase 1/2·NCT06647407·750 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Rotavirus vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rotavirus vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rotavirus vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Preclinical[1]
Company: Sanofi

Rotavirus vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Trials by Indication[1]

Vaccine6 trials

Rotavirus Vaccine4 trials

Immunogenicity3 trials

Gastroenteritis2 trials

Pediatric2 trials

Vaccines2 trials

Respiratory Syncytial Virus1 trial

Meningococcal Disease1 trial

References

Drug Info

Quick Facts

Related News